Founder and CEO of a VC-backed bioproduction company. Brings rare dual fluency in biology and business — capable of leading both the lab floor and the boardroom.
Exosome Market Focus
Last 3 years deeply focused on the exosome sector, with extensive due diligence on cross-border operations, manufacturing partnerships, regulatory landscape, clinic/doctor relationships globally, and deep competitive knoweldge.
Technical / Core Expertise
Bioreactor Systems
10+ years designing scalable bioreactor systems up to 200L for therapeutic-grade biologics manufacturing.
Hollow Fiber Perfusion
Hands-on operator across multiple hollow fiber perfusion platforms - the gold standard for high yield exosome production at clinical scale.
GMP Bioprocess Engineering
End-to-end GMP process design across multiple product lines, from IND-enabling studies through commercial-scale manufacturing readiness.
The rare operator who understands both the biology and the business.
Market Analysis
A Market at an Inflection Point
$1.6B+
Market by 2034
Exosome based regenerative aesthetics projected market size, representing a high growth segment with accelerating clinical adoption.
2025–26
Regulatory Window
Florida SB1768 are opening commercial avenues for US produced therapeutic exosomes — right now.
Competitive Differentiation
Signal's GMP certified, US produced, MSC derived exosomes offer a decisive quality and compliance advantage over key competitors:
Revenue Opportunity
Potential Clients: Scale & Buying Power
The addressable buyer universe is substantial, spanning four high-value clinical segments with meaningful per-account revenue potential.
Total Addressable Buyer Universe
11,000–19,500 qualified accounts globally across all four segments, with strong concentration in the US, Mexico, and Asia-Pacific.
Year 1 Revenue Target
Conservative ramp of 40–80 activated accounts translates to $2.5M–$5.0M in first-year revenue — achievable with existing network and no cold outreach required.
Geographic Strategy
Countries With Active Contacts
USA / Florida — Anchor Market
$500M+ domestic market. 1,500–3,000 national buyers, with Florida as the highest-density state for aesthetic and longevity medicine. Favorable state-level legislation (SB1768) creates immediate commercial entry. CEO is Florida-based.
Mexico / Mexico — Medical Tourism Hub
$200M regional market. Mexico is the anchor — a globally recognized medical tourism destination with 400–800 qualified buyers in-country alone. Existing relationships accelerate market entry and support cross-border patient referral flows.
Asia / Taiwan — APAC Growth Channel
$900M Far East market. Existing manufacturing partner relationships and an established APAC clinical network provide a significant structural advantage. Taiwan serves as the regional gateway for broader Asia-Pacific commercial expansion.
Compensation Structure
Expected Compensation & Structure
Total Package Overview
$150,000–$180,000
Base Salary
Commensurate with CEO/founder-operator responsibility.
US-based with regular travel to Mexico and Asia-Pacific for clinical partner engagement.
Full Compensation Components
Base Salary
$150,000–$180,000 USD/year, reflecting the operational and executive scope of the role.
Equity Participation
Commensurate with a CEO/founder-operator contribution — structured to align long term incentives with Signal's growth trajectory and NurExone's shareholder value creation.
Performance Bonus
Milestone tied bonus structure linked directly to revenue targets, account acquisition, and key commercial deliverables — ensuring accountability and upside alignment.
Investment Thesis
Why This Works
Three forces are converging simultaneously — and Signal sits at the exact intersection of all three.
The Right Product
GMP-certified, US produced, MSC derived exosomes. Regulatory ready, clinically credible, and meaningfully differentiated from every competitor in the current market.
The Right Moment
2025–2026 US state legislation is creating a legal commercial runway that did not exist 18 months ago. First mover advantage is available — but only briefly.
The Right Operator
A CEO with bioproduction depth, prior VC-backed company leadership, and an established exosome clinical network. Day one execution capacity — no ramp up period required.
Signal is a near term revenue opportunity, not a speculative bet. The product is real, the market is open, and the operator is ready.
Revenue Strategy
Day One Revenue — No Waiting for Production
Signal generates revenue immediately — through proven third party supply, while ExoTop production scales.
Interim Supply Partners
Aexo Bio (Taiwan) — TSC-derived exosomes, clinically characterized. Klothea (Austria) — Klotho exosomes, clinically validated. Available now.
Revenue From Day One
Activate accounts, build distributor relationships, and establish a commercial footprint — before ExoTop is production-ready.
Seamless Transition
When ExoTop launches, Signal flips existing accounts to ExoTop supply. Customer base already built. Zero restart.
Commercial on arrival, not commercial on production.
Financial Planning
Year 1 Budget — Signal Distribution Model
Signal purchases finished GMP-grade product from NurExone at cost and resells to clinics and physicians at margin. No production infrastructure required.
Headcount (3 FTE)
TOTAL fully loaded (incl. 20% benefits): ~$348,000
Operating Expenses
P&L Summary
Asset-light model. Under $1M to launch. Profitable in Year 1 at both scenarios.